Dr. Lee is a Staff Bioinformatics Scientist at Guardant Health, a precision oncology company focused on advancing cancer detection and treatment through genomic technologies. Guardant’s products span a range of clinical applications, including blood-based screening for early cancer detection, minimal residual disease (MRD) monitoring following treatment, and comprehensive biomarker profiling to guide therapy selection and predict drug response. In his role, he contributes to the development of new diagnostic assays and supports the design and implementation of bioinformatics pipelines that enable robust, scalable analysis of sequencing data. He is involved in setting up and maintaining sample quality control metrics, contributing to standard operating procedures (SOPs), and supporting regulatory activities such as CLIA validation and FDA submissions. His work also includes algorithm development, particularly in areas that aim to improve the accuracy and sensitivity of genomic variant detection and contamination analysis. He collaborates closely with wet lab teams, software engineers, and clinical and regulatory groups to ensure that the bioinformatics components of their workflows meet both scientific and regulatory standards. Overall, his focus is on delivering reliable, clinically actionable insights from sequencing data, with the goal of improving cancer care across detection, monitoring, and treatment selection.

Biotech entrepreneur and venture capital leader with over 25 years of experience in life science investment and drug development. As former fund manager at Taian Technology, the only venture capital firm in Taiwan exclusively focused on biotech and pharmaceuticals, I achieved an average return of 5x and IRR of 67%. Currently serving as CEO of Topmunnity Therapeutics, a platform-driven biotech company developing tumor-selective ADCs, CAR-T cell therapies, and AI-generated antibodies. Proven success in company building, deep-tech R&D leadership, capital raising, and advancing novel immuno-oncology assets from concept to preclinical stage.

Prairie Lin is a biopharma commercial leader with over a decade of experience across the U.S. and Asia. With a proven track record of launching and growing brands in oncology, neuroscience, and nutrition, she brings deep expertise in brand strategy, lifecycle management, and patient-centered execution. Her career spans the full spectrum of the healthcare industry—from startups to mid-sized companies like Exelixis to global pharmaceutical leaders such as Genentech, Abbott, and Eli Lilly. Like a conduit between scientific innovation and real-world impact, she has held roles in sales, marketing, commercial strategy, and pricing—giving her a 360-degree perspective on how to build and scale brands in complex markets. She has led multiple successful product launches, blending strategic thinking with frontline execution to drive meaningful results. Now based in the San Francisco Bay Area, she holds an MBA from Northwestern University’s Kellogg School of Management and a BBA from National Taiwan University. As a proud Taiwanese professional, she is passionate about giving back—sharing her journey and lessons learned to inspire and empower the next generation of Taiwanese talent pursuing careers in healthcare.